APO Research
Talk to an analyst

APO RESEARCH · REPORT

External Anti-infective Preparations

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global External Anti-infective Preparations Market Outlook and Growth Opportunities 2026

23 December 2025206 pages

Choose your research edition.

Industry ResearchExternal Anti-infective Preparations Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal External Anti-infective Preparations Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal External Anti-infective Preparations Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal External Anti-infective Preparations Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal External Anti-infective Preparations Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global External Anti-infective Preparations market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for External Anti-infective Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for External Anti-infective Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for External Anti-infective Preparations is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the External Anti-infective Preparations market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the External Anti-infective Preparations market include SK-SF, Zhejiang Funo Pharmaceuticals, Teva, Sun Pharmaceutical, Shandong Jingwei Pharmaceuticals, Sandoz, J & J, Liaoning Xingao Pharmaceuticals and Jiangsu Zhiyuan Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global External Anti-infective Preparations market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of External Anti-infective Preparations and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents External Anti-infective Preparations revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global External Anti-infective Preparations market.

External Anti-infective Preparations Segment by Company

SK-SF

Zhejiang Funo Pharmaceuticals

Teva

Sun Pharmaceutical

Shandong Jingwei Pharmaceuticals

Sandoz

J & J

Liaoning Xingao Pharmaceuticals

Jiangsu Zhiyuan Pharmaceuticals

Jiangsu Fubang Pharmaceuticals

Hubei Renfu

Bayer

STADA Arzneimittel

LEO Pharma

Kaken Pharmaceutical

Haleon

Glenmark Pharmaceuticals

Galderma

Bausch Health

Almirall

External Anti-infective Preparations Segment by Type

Ointment

Solution

Gel

Other

External Anti-infective Preparations Segment by Application

Hospital

Retail Phamracy

Other

External Anti-infective Preparations Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global External Anti-infective Preparations status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the External Anti-infective Preparations key companies, revenue, market share, and recent developments.

3. To split the External Anti-infective Preparations breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions External Anti-infective Preparations market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify External Anti-infective Preparations significant trends, drivers, influence factors in global and regions.

6. To analyze External Anti-infective Preparations competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global External Anti-infective Preparations market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of External Anti-infective Preparations and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of External Anti-infective Preparations.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global External Anti-infective Preparations industry.

Chapter 3: Detailed analysis of External Anti-infective Preparations company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of External Anti-infective Preparations in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of External Anti-infective Preparations in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. External Anti-infective Preparations Industry Trends Table 2. External Anti-infective Preparations Industry Drivers Table 3. External Anti-infective Preparations Industry Opportunities and Challenges Table 4. External Anti-infective Preparations Industry Restraints Table 5. Global External Anti-infective Preparations Revenue by Company (US$ Million) & (2021-2026) Table 6. Global External Anti-infective Preparations Revenue Share by Company (2021-2026) Table 7. Global External Anti-infective Preparations Company Ranking, (2024-2026) & (US$ Million) Table 8. Global External Anti-infective Preparations Key Company Manufacturing Base & Headquarters Table 9. Global External Anti-infective Preparations Company, Product Type & Application Table 10. Global External Anti-infective Preparations Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global External Anti-infective Preparations by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ointment Table 15. Significant Companies of Solution Table 16. Significant Companies of Gel Table 17. Significant Companies of Other Table 18. Global External Anti-infective Preparations Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global External Anti-infective Preparations Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global External Anti-infective Preparations Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global External Anti-infective Preparations Sales Value Share by Type (2021-2026) Table 22. Global External Anti-infective Preparations Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Retail Phamracy Table 25. Significant Companies of Other Table 26. Global External Anti-infective Preparations Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global External Anti-infective Preparations Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global External Anti-infective Preparations Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global External Anti-infective Preparations Sales Value Share by Application (2021-2026) Table 30. Global External Anti-infective Preparations Sales Value Share by Application (2027-2032) Table 31. Global External Anti-infective Preparations Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global External Anti-infective Preparations Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global External Anti-infective Preparations Sales Value Share by Region (2021-2026) Table 34. Global External Anti-infective Preparations Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global External Anti-infective Preparations Sales Value Share by Region (2027-2032) Table 36. Global External Anti-infective Preparations Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global External Anti-infective Preparations Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global External Anti-infective Preparations Sales Value Market Share by Country (2021-2026) Table 39. Global External Anti-infective Preparations Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global External Anti-infective Preparations Sales Value Market Share by Country (2027-2032) Table 41. SK-SF Company Information Table 42. SK-SF Business Overview Table 43. SK-SF External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. SK-SF External Anti-infective Preparations Product Portfolio Table 45. SK-SF Recent Development Table 46. Zhejiang Funo Pharmaceuticals Company Information Table 47. Zhejiang Funo Pharmaceuticals Business Overview Table 48. Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Product Portfolio Table 50. Zhejiang Funo Pharmaceuticals Recent Development Table 51. Teva Company Information Table 52. Teva Business Overview Table 53. Teva External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Teva External Anti-infective Preparations Product Portfolio Table 55. Teva Recent Development Table 56. Sun Pharmaceutical Company Information Table 57. Sun Pharmaceutical Business Overview Table 58. Sun Pharmaceutical External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Sun Pharmaceutical External Anti-infective Preparations Product Portfolio Table 60. Sun Pharmaceutical Recent Development Table 61. Shandong Jingwei Pharmaceuticals Company Information Table 62. Shandong Jingwei Pharmaceuticals Business Overview Table 63. Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Product Portfolio Table 65. Shandong Jingwei Pharmaceuticals Recent Development Table 66. Sandoz Company Information Table 67. Sandoz Business Overview Table 68. Sandoz External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Sandoz External Anti-infective Preparations Product Portfolio Table 70. Sandoz Recent Development Table 71. J & J Company Information Table 72. J & J Business Overview Table 73. J & J External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. J & J External Anti-infective Preparations Product Portfolio Table 75. J & J Recent Development Table 76. Liaoning Xingao Pharmaceuticals Company Information Table 77. Liaoning Xingao Pharmaceuticals Business Overview Table 78. Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Product Portfolio Table 80. Liaoning Xingao Pharmaceuticals Recent Development Table 81. Jiangsu Zhiyuan Pharmaceuticals Company Information Table 82. Jiangsu Zhiyuan Pharmaceuticals Business Overview Table 83. Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Product Portfolio Table 85. Jiangsu Zhiyuan Pharmaceuticals Recent Development Table 86. Jiangsu Fubang Pharmaceuticals Company Information Table 87. Jiangsu Fubang Pharmaceuticals Business Overview Table 88. Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Product Portfolio Table 90. Jiangsu Fubang Pharmaceuticals Recent Development Table 91. Hubei Renfu Company Information Table 92. Hubei Renfu Business Overview Table 93. Hubei Renfu External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Hubei Renfu External Anti-infective Preparations Product Portfolio Table 95. Hubei Renfu Recent Development Table 96. Bayer Company Information Table 97. Bayer Business Overview Table 98. Bayer External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Bayer External Anti-infective Preparations Product Portfolio Table 100. Bayer Recent Development Table 101. STADA Arzneimittel Company Information Table 102. STADA Arzneimittel Business Overview Table 103. STADA Arzneimittel External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. STADA Arzneimittel External Anti-infective Preparations Product Portfolio Table 105. STADA Arzneimittel Recent Development Table 106. LEO Pharma Company Information Table 107. LEO Pharma Business Overview Table 108. LEO Pharma External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. LEO Pharma External Anti-infective Preparations Product Portfolio Table 110. LEO Pharma Recent Development Table 111. Kaken Pharmaceutical Company Information Table 112. Kaken Pharmaceutical Business Overview Table 113. Kaken Pharmaceutical External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Kaken Pharmaceutical External Anti-infective Preparations Product Portfolio Table 115. Kaken Pharmaceutical Recent Development Table 116. Haleon Company Information Table 117. Haleon Business Overview Table 118. Haleon External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. Haleon External Anti-infective Preparations Product Portfolio Table 120. Haleon Recent Development Table 121. Glenmark Pharmaceuticals Company Information Table 122. Glenmark Pharmaceuticals Business Overview Table 123. Glenmark Pharmaceuticals External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Glenmark Pharmaceuticals External Anti-infective Preparations Product Portfolio Table 125. Glenmark Pharmaceuticals Recent Development Table 126. Galderma Company Information Table 127. Galderma Business Overview Table 128. Galderma External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Galderma External Anti-infective Preparations Product Portfolio Table 130. Galderma Recent Development Table 131. Bausch Health Company Information Table 132. Bausch Health Business Overview Table 133. Bausch Health External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. Bausch Health External Anti-infective Preparations Product Portfolio Table 135. Bausch Health Recent Development Table 136. Almirall Company Information Table 137. Almirall Business Overview Table 138. Almirall External Anti-infective Preparations Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Almirall External Anti-infective Preparations Product Portfolio Table 140. Almirall Recent Development Table 141. Research Programs/Design for This Report Table 142. Authors List of This Report Table 143. Secondary Sources Table 144. Primary Sources List of Figures Figure 1. External Anti-infective Preparations Product Image Figure 2. Global External Anti-infective Preparations Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global External Anti-infective Preparations Market Size (2021-2032) & (US$ Million) Figure 4. Global External Anti-infective Preparations Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ointment Image Figure 8. Solution Image Figure 9. Gel Image Figure 10. Other Image Figure 11. Global External Anti-infective Preparations Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global External Anti-infective Preparations Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global External Anti-infective Preparations Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Retail Phamracy Image Figure 16. Other Image Figure 17. Global External Anti-infective Preparations Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global External Anti-infective Preparations Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global External Anti-infective Preparations Sales Value Share by Application (2021-2032) Figure 20. Global External Anti-infective Preparations Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global External Anti-infective Preparations Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America External Anti-infective Preparations Sales Value (2021-2032) & (US$ Million) Figure 23. North America External Anti-infective Preparations Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe External Anti-infective Preparations Sales Value (2021-2032) & (US$ Million) Figure 25. Europe External Anti-infective Preparations Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific External Anti-infective Preparations Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific External Anti-infective Preparations Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America External Anti-infective Preparations Sales Value (2021-2032) & (US$ Million) Figure 29. South America External Anti-infective Preparations Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa External Anti-infective Preparations Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa External Anti-infective Preparations Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt External Anti-infective Preparations Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Ointment
  • Solution
  • Gel
  • Other
Applications
  • Hospital
  • Retail Phamracy
  • Other
Companies covered
  • SK-SF
  • Zhejiang Funo Pharmaceuticals
  • Teva
  • Sun Pharmaceutical
  • Shandong Jingwei Pharmaceuticals
  • Sandoz
  • J & J
  • Liaoning Xingao Pharmaceuticals
  • Jiangsu Zhiyuan Pharmaceuticals
  • Jiangsu Fubang Pharmaceuticals
  • Hubei Renfu
  • Bayer
  • STADA Arzneimittel
  • LEO Pharma
  • Kaken Pharmaceutical
  • Haleon
  • Glenmark Pharmaceuticals
  • Galderma
  • Bausch Health
  • Almirall

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global External Anti-infective Preparations Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global External Anti-infective Preparations Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 External Anti-infective Preparations Market Dynamics
  1. 2.1 External Anti-infective Preparations Industry Trends
  2. 2.2 External Anti-infective Preparations Industry Drivers
  3. 2.3 External Anti-infective Preparations Industry Opportunities and Challenges
  4. 2.4 External Anti-infective Preparations Industry Restraints
3 External Anti-infective Preparations Market by Company
  1. 3.1 Global External Anti-infective Preparations Company Revenue Ranking in 2025
  2. 3.2 Global External Anti-infective Preparations Revenue by Company (2021-2026)
  3. 3.3 Global External Anti-infective Preparations Company Ranking (2024-2026)
  4. 3.4 Global External Anti-infective Preparations Company Manufacturing Base and Headquarters
  5. 3.5 Global External Anti-infective Preparations Company Product Type and Application
  6. 3.6 Global External Anti-infective Preparations Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global External Anti-infective Preparations Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 External Anti-infective Preparations Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 External Anti-infective Preparations Market by Type
  1. 4.1 External Anti-infective Preparations Type Introduction
  2. 4.1.1 Ointment
  3. 4.1.2 Solution
  4. 4.1.3 Gel
  5. 4.1.4 Other
  6. 4.2 Global External Anti-infective Preparations Sales Value by Type
  7. 4.2.1 Global External Anti-infective Preparations Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global External Anti-infective Preparations Sales Value by Type (2021-2032)
  9. 4.2.3 Global External Anti-infective Preparations Sales Value Share by Type (2021-2032)
5 External Anti-infective Preparations Market by Application
  1. 5.1 External Anti-infective Preparations Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Phamracy
  4. 5.1.3 Other
  5. 5.2 Global External Anti-infective Preparations Sales Value by Application
  6. 5.2.1 Global External Anti-infective Preparations Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global External Anti-infective Preparations Sales Value by Application (2021-2032)
  8. 5.2.3 Global External Anti-infective Preparations Sales Value Share by Application (2021-2032)
6 External Anti-infective Preparations Regional Value Analysis
  1. 6.1 Global External Anti-infective Preparations Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global External Anti-infective Preparations Sales Value by Region (2021-2032)
  3. 6.2.1 Global External Anti-infective Preparations Sales Value by Region: 2021-2026
  4. 6.2.2 Global External Anti-infective Preparations Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America External Anti-infective Preparations Sales Value (2021-2032)
  7. 6.3.2 North America External Anti-infective Preparations Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe External Anti-infective Preparations Sales Value (2021-2032)
  10. 6.4.2 Europe External Anti-infective Preparations Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific External Anti-infective Preparations Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific External Anti-infective Preparations Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America External Anti-infective Preparations Sales Value (2021-2032)
  16. 6.6.2 South America External Anti-infective Preparations Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa External Anti-infective Preparations Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa External Anti-infective Preparations Sales Value Share by Country, 2025 VS 2032
7 External Anti-infective Preparations Country-level Value Analysis
  1. 7.1 Global External Anti-infective Preparations Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global External Anti-infective Preparations Sales Value by Country (2021-2032)
  3. 7.2.1 Global External Anti-infective Preparations Sales Value by Country (2021-2026)
  4. 7.2.2 Global External Anti-infective Preparations Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt External Anti-infective Preparations Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt External Anti-infective Preparations Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt External Anti-infective Preparations Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 SK-SF
  2. 8.1.1 SK-SF Company Information
  3. 8.1.2 SK-SF Business Overview
  4. 8.1.3 SK-SF External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  5. 8.1.4 SK-SF External Anti-infective Preparations Product Portfolio
  6. 8.1.5 SK-SF Recent Developments
  7. 8.2 Zhejiang Funo Pharmaceuticals
  8. 8.2.1 Zhejiang Funo Pharmaceuticals Company Information
  9. 8.2.2 Zhejiang Funo Pharmaceuticals Business Overview
  10. 8.2.3 Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Product Portfolio
  12. 8.2.5 Zhejiang Funo Pharmaceuticals Recent Developments
  13. 8.3 Teva
  14. 8.3.1 Teva Company Information
  15. 8.3.2 Teva Business Overview
  16. 8.3.3 Teva External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Teva External Anti-infective Preparations Product Portfolio
  18. 8.3.5 Teva Recent Developments
  19. 8.4 Sun Pharmaceutical
  20. 8.4.1 Sun Pharmaceutical Company Information
  21. 8.4.2 Sun Pharmaceutical Business Overview
  22. 8.4.3 Sun Pharmaceutical External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Sun Pharmaceutical External Anti-infective Preparations Product Portfolio
  24. 8.4.5 Sun Pharmaceutical Recent Developments
  25. 8.5 Shandong Jingwei Pharmaceuticals
  26. 8.5.1 Shandong Jingwei Pharmaceuticals Company Information
  27. 8.5.2 Shandong Jingwei Pharmaceuticals Business Overview
  28. 8.5.3 Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Product Portfolio
  30. 8.5.5 Shandong Jingwei Pharmaceuticals Recent Developments
  31. 8.6 Sandoz
  32. 8.6.1 Sandoz Company Information
  33. 8.6.2 Sandoz Business Overview
  34. 8.6.3 Sandoz External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Sandoz External Anti-infective Preparations Product Portfolio
  36. 8.6.5 Sandoz Recent Developments
  37. 8.7 J & J
  38. 8.7.1 J & J Company Information
  39. 8.7.2 J & J Business Overview
  40. 8.7.3 J & J External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  41. 8.7.4 J & J External Anti-infective Preparations Product Portfolio
  42. 8.7.5 J & J Recent Developments
  43. 8.8 Liaoning Xingao Pharmaceuticals
  44. 8.8.1 Liaoning Xingao Pharmaceuticals Company Information
  45. 8.8.2 Liaoning Xingao Pharmaceuticals Business Overview
  46. 8.8.3 Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Product Portfolio
  48. 8.8.5 Liaoning Xingao Pharmaceuticals Recent Developments
  49. 8.9 Jiangsu Zhiyuan Pharmaceuticals
  50. 8.9.1 Jiangsu Zhiyuan Pharmaceuticals Company Information
  51. 8.9.2 Jiangsu Zhiyuan Pharmaceuticals Business Overview
  52. 8.9.3 Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Product Portfolio
  54. 8.9.5 Jiangsu Zhiyuan Pharmaceuticals Recent Developments
  55. 8.10 Jiangsu Fubang Pharmaceuticals
  56. 8.10.1 Jiangsu Fubang Pharmaceuticals Company Information
  57. 8.10.2 Jiangsu Fubang Pharmaceuticals Business Overview
  58. 8.10.3 Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Product Portfolio
  60. 8.10.5 Jiangsu Fubang Pharmaceuticals Recent Developments
  61. 8.11 Hubei Renfu
  62. 8.11.1 Hubei Renfu Company Information
  63. 8.11.2 Hubei Renfu Business Overview
  64. 8.11.3 Hubei Renfu External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Hubei Renfu External Anti-infective Preparations Product Portfolio
  66. 8.11.5 Hubei Renfu Recent Developments
  67. 8.12 Bayer
  68. 8.12.1 Bayer Company Information
  69. 8.12.2 Bayer Business Overview
  70. 8.12.3 Bayer External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bayer External Anti-infective Preparations Product Portfolio
  72. 8.12.5 Bayer Recent Developments
  73. 8.13 STADA Arzneimittel
  74. 8.13.1 STADA Arzneimittel Company Information
  75. 8.13.2 STADA Arzneimittel Business Overview
  76. 8.13.3 STADA Arzneimittel External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  77. 8.13.4 STADA Arzneimittel External Anti-infective Preparations Product Portfolio
  78. 8.13.5 STADA Arzneimittel Recent Developments
  79. 8.14 LEO Pharma
  80. 8.14.1 LEO Pharma Company Information
  81. 8.14.2 LEO Pharma Business Overview
  82. 8.14.3 LEO Pharma External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  83. 8.14.4 LEO Pharma External Anti-infective Preparations Product Portfolio
  84. 8.14.5 LEO Pharma Recent Developments
  85. 8.15 Kaken Pharmaceutical
  86. 8.15.1 Kaken Pharmaceutical Company Information
  87. 8.15.2 Kaken Pharmaceutical Business Overview
  88. 8.15.3 Kaken Pharmaceutical External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Kaken Pharmaceutical External Anti-infective Preparations Product Portfolio
  90. 8.15.5 Kaken Pharmaceutical Recent Developments
  91. 8.16 Haleon
  92. 8.16.1 Haleon Company Information
  93. 8.16.2 Haleon Business Overview
  94. 8.16.3 Haleon External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Haleon External Anti-infective Preparations Product Portfolio
  96. 8.16.5 Haleon Recent Developments
  97. 8.17 Glenmark Pharmaceuticals
  98. 8.17.1 Glenmark Pharmaceuticals Company Information
  99. 8.17.2 Glenmark Pharmaceuticals Business Overview
  100. 8.17.3 Glenmark Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Glenmark Pharmaceuticals External Anti-infective Preparations Product Portfolio
  102. 8.17.5 Glenmark Pharmaceuticals Recent Developments
  103. 8.18 Galderma
  104. 8.18.1 Galderma Company Information
  105. 8.18.2 Galderma Business Overview
  106. 8.18.3 Galderma External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Galderma External Anti-infective Preparations Product Portfolio
  108. 8.18.5 Galderma Recent Developments
  109. 8.19 Bausch Health
  110. 8.19.1 Bausch Health Company Information
  111. 8.19.2 Bausch Health Business Overview
  112. 8.19.3 Bausch Health External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Bausch Health External Anti-infective Preparations Product Portfolio
  114. 8.19.5 Bausch Health Recent Developments
  115. 8.20 Almirall
  116. 8.20.1 Almirall Company Information
  117. 8.20.2 Almirall Business Overview
  118. 8.20.3 Almirall External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Almirall External Anti-infective Preparations Product Portfolio
  120. 8.20.5 Almirall Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst